• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential of heparin and nafamostat combination therapy for COVID-19.

作者信息

Asakura Hidesaku, Ogawa Haruhiko

机构信息

Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.

Department of Environmental and Preventive Medicine, Kanazawa University, Kanazawa, Japan.

出版信息

J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6.

DOI:10.1111/jth.14858
PMID:32302456
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9906352/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59f/9906352/a18834751e8c/jth14858-fig-0001-m_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59f/9906352/a18834751e8c/jth14858-fig-0001-m_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d59f/9906352/a18834751e8c/jth14858-fig-0001-m_lrg.jpg

相似文献

1
Potential of heparin and nafamostat combination therapy for COVID-19.肝素与那法莫司他联合治疗新冠肺炎的潜力
J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6.
2
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.新型冠状病毒肺炎患者使用甲磺酸萘莫司他和法匹拉韦治疗的相关不良事件。
Crit Care. 2020 Aug 12;24(1):497. doi: 10.1186/s13054-020-03227-4.
3
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
4
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.肝素在治疗新冠肺炎患者中的抗凝和抗心律失常作用。
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
5
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.羟氯喹联合甲磺酸萘莫司他连续性血液透析滤过治疗重症 COVID-19 患者的临床疗效。
J Infect Chemother. 2020 Dec;26(12):1319-1323. doi: 10.1016/j.jiac.2020.08.001. Epub 2020 Aug 6.
6
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.三例 COVID-19 肺炎老年患者需要氧疗时使用那屈肝素的治疗案例。
Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.
7
The versatile heparin in COVID-19.新冠疫情中用途广泛的肝素。
J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27.
8
Differentiating biochemical from clinical heparin resistance in COVID-19.区分COVID-19中生化性与临床性肝素抵抗
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
9
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care.肝素失效与新冠病毒病：我们是否应探索其他抗凝剂？一份关于重症监护病房新冠病毒病患者抗凝作用体外恢复情况的观察报告
Thromb Res. 2020 Nov;195:226-227. doi: 10.1016/j.thromres.2020.08.010. Epub 2020 Aug 9.
10
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?新冠病毒感染中的肺栓塞或肺血栓形成？使用高剂量肝素进行血栓预防的建议是否合理？
Thromb Haemost. 2020 Aug;120(8):1230-1232. doi: 10.1055/s-0040-1712097. Epub 2020 Apr 29.

引用本文的文献

1
Post-COVID Mucormycosis-Conceptual Etiology and New Treatment Options.新冠后毛霉菌病——概念性病因及新的治疗选择
J Maxillofac Oral Surg. 2024 Dec;23(6):1516-1527. doi: 10.1007/s12663-024-02124-5. Epub 2024 May 16.
2
Emerging patterns of hypercoagulability associated with critical COVID-19: A review.与重症新型冠状病毒肺炎相关的高凝状态新趋势：综述
Trends Anaesth Crit Care. 2020 Oct;34:4-13. doi: 10.1016/j.tacc.2020.07.004. Epub 2020 Jul 9.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.

本文引用的文献

1
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
2
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Nafamostat Mesylate for the Hypercoagulable State of SARS-CoV-2 With Renal Replacement Therapy: A Case Report.甲磺酸萘莫司他用于接受肾脏替代治疗的新型冠状病毒肺炎高凝状态：一例报告
Cureus. 2024 Jan 20;16(1):e52641. doi: 10.7759/cureus.52641. eCollection 2024 Jan.
5
Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.甲磺酸萘莫司他在终末期肾衰竭患者中的疗效和安全性。
World J Clin Cases. 2024 Jan 6;12(1):68-75. doi: 10.12998/wjcc.v12.i1.68.
6
Multisite spontaneous hematomas and bleeding in critically ill Chinese patients with COVID-19: two case reports and a literature review.多部位自发性血肿和出血：COVID-19 危重症中国患者的两例病例报告和文献复习。
BMC Infect Dis. 2024 Jan 18;24(1):101. doi: 10.1186/s12879-024-09012-w.
7
Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective.将美国食品药品监督管理局（FDA）批准的药物西替利司他、阿比特龙、二碘羟基喹啉、贝沙罗汀和瑞德西韦重新用作针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的RNA依赖性RNA聚合酶的潜在抑制剂：一项计算机模拟比较研究。
Inform Med Unlocked. 2023;36:101147. doi: 10.1016/j.imu.2022.101147. Epub 2022 Dec 8.
8
Small molecules in the treatment of COVID-19.小分子药物治疗 COVID-19。
Signal Transduct Target Ther. 2022 Dec 5;7(1):387. doi: 10.1038/s41392-022-01249-8.
9
Not Just Anticoagulation-New and Old Applications of Heparin.肝素的新老应用：不止抗凝。
Molecules. 2022 Oct 17;27(20):6968. doi: 10.3390/molecules27206968.
10
Exacerbation of Pre-existing Neurological Symptoms With COVID-19 in Patients With Chronic Neurological Diseases: An Updated Systematic Review.慢性神经疾病患者感染新冠病毒后原有神经症状的加重：一项更新的系统评价
Cureus. 2022 Sep 18;14(9):e29297. doi: 10.7759/cureus.29297. eCollection 2022 Sep.
中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
5
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
6
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.使用基于分裂蛋白的细胞-细胞融合试验鉴定那法莫司他为中东呼吸综合征冠状病毒S蛋白介导的膜融合的有效抑制剂。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. doi: 10.1128/AAC.01043-16. Print 2016 Nov.
7
Classifying types of disseminated intravascular coagulation: clinical and animal models.弥散性血管内凝血的分类：临床和动物模型。
J Intensive Care. 2014 Mar 6;2(1):20. doi: 10.1186/2052-0492-2-20. eCollection 2014.
8
Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.甲磺纳法莫司他（FUT-175）的药理学研究。I. 体内外实验中对蛋白酶活性的抑制作用
Jpn J Pharmacol. 1984 Jul;35(3):203-27. doi: 10.1254/jjp.35.203.